Compare RKTO & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RKTO | ALLR |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 21.5M |
| IPO Year | 2018 | 2021 |
| Metric | RKTO | ALLR |
|---|---|---|
| Price | $0.68 | $1.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | ★ 299.6K | 70.9K |
| Earning Date | N/A | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.69 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $320,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.68 | $0.77 |
| 52 Week High | $1.19 | $1.92 |
| Indicator | RKTO | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 33.28 | 56.83 |
| Support Level | N/A | $1.22 |
| Resistance Level | $0.78 | $1.42 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 18.23 | 70.00 |
Rocket One Inc is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic AI chip technology designed for radiation-tolerant, energy-constrained environments such as low-Earth orbit, deep-space platforms, and defense systems. The company also intends to pursue opportunities related to nano-launch systems and nanosatellite deployment. In addition, its biotechnology operations, conducted through a wholly owned subsidiary, include development programs such as HT-001, HT-KIT, HT-ALZ, and a GDNF-based metabolic program.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.